Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 19.46% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 19.46% decrease, with the full-year FY2025 number at $1.0 million, down 19.46% from a year prior.
  • Gains from Sales and Divestitures was $1.0 million for Q4 2025 at Beam Therapeutics, up from $783939.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q4 2024 to a low of $283186.0 in Q1 2022.
  • A 5-year average of $583177.8 and a median of $481075.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 58.44% in 2022, then soared 177.31% in 2024.
  • Beam Therapeutics' Gains from Sales and Divestitures stood at $1.0 million in 2021, then crashed by 58.44% to $424303.0 in 2022, then grew by 10.66% to $469531.0 in 2023, then skyrocketed by 177.31% to $1.3 million in 2024, then dropped by 19.46% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Gains from Sales and Divestitures are $1.0 million (Q4 2025), $783939.0 (Q3 2025), and $688359.0 (Q2 2025).